摘要
二甲双胍是2型糖尿病(type 2 diabetes mellitus,T2DM)的一线降糖药物,除了降低血糖外,研究显示其可能对T2DM患者的心血管事件风险有一定影响。与其他降糖药相比,单用二甲双胍可降低T2DM患者心血管事件的风险;另外,二甲双胍与其他降糖药物联合使用时,对患者的心血管风险也有不同的影响。在肾功能轻度减退的T2DM患者中应用二甲双胍不会增加心血管事件风险,但对于肾功能衰竭的患者,应用二甲双胍可能与较高的卒中和全因死亡风险有关。
Metformin is the first-line therapeutic drug for type 2 diabetes mellitus(T2DM).In addition to lowering blood glucose,studies have shown that it has an effect on the risk of cardiovascular events in T2DM patients.Compared with other glucose-lowering agents,metformin monotherapy was associated with lowering risk of cardiovascular events in T2DM patients.Metformin-based combination therapy has different effects on cardiovascular risk of T2DM patients.Metformin does not increase the risk of cardiovascular events in T2DM patients with mild renal impairment,while it may be associated with a higher risk of stroke and all-cause mortality in T2DM patients with renal failure.
作者
张敏
李洪伟
隋长百
高越
赵咏梅
徐丽霞
孟霞
ZHANG Min;LI Hong-Wei;SUI Chang-Bai;GAO Yue;ZHAO Yong-Mei;XU Li-Xia;MENG Xia(China National Clinical Research Center for Neurological Disease,Beijing 100070,China;Department of Geriatric Medicine,Peking University Care Luzhong Hospital,Shandong Province Zibo 255400,China;Department of Neurology,Yantai Beihai Hospital,Shandong Province Yantai 265701,China;Department of Emergency,Kailuan General Hospital,Hebei Province Tangshan 063000,China;Department of Neurology,Beijing Tiantan Hospital,Capital Medical University,Beijing 100070,China)
出处
《中国卒中杂志》
2021年第4期408-412,共5页
Chinese Journal of Stroke
基金
国家重点研发计划(2018YFC1312903)
干细胞临床研究的方法学平台与质控体系研究(Z181100001818001)。
关键词
二甲双胍
心血管事件
卒中
Metformin
Cardiovascular events
Stroke
